Comparative Pharmacology
Head-to-head clinical analysis: IOBENGUANE I 123 versus SETHOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOBENGUANE I 123 versus SETHOTOPE.
IOBENGUANE I-123 vs SETHOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iobenguane I-123 is a radiopharmaceutical analog of norepinephrine that is taken up by adrenergic neurons and neuroendocrine tumors via the norepinephrine transporter (NET). It localizes in tissues rich in sympathetic innervation and tumors expressing NET, enabling scintigraphic imaging.
SETHOTOPE is a radiolabeled monoclonal antibody that binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells, delivering beta radiation (177Lu) to cause DNA damage and cell death.
Intravenous administration of 5 mCi (185 MBq) as a single dose for imaging.
1.0 mg IV every 12 hours for 7 days.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours; clinically relevant for imaging timing (optimal scanning at 24 hours post-injection)
Terminal elimination half-life: 12 hours (range 10-14 h); clinically, dosing interval is 12-24 h to maintain therapeutic levels
Renal: 40-60% as unchanged iobenguane within 24 hours; biliary/fecal: minimal (<5%)
Renal: 70% as unchanged drug; fecal: 25% as metabolites; biliary: 5%
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical